There are 2789 resources available
1509MO - Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials
Presenter: Justin Moyers
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
1510MO_PR - European cancer patients’ perspectives on Immunotherapy
Presenter: Paraskevas Kosmidis
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
1172MO - Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
Presenter: Mariona Riudavets Melia
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
654MO - A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)
Presenter: Giuseppe Procopio
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Q&A
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Yes
Presenter: Isabelle Ray-Coquard
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
No
Presenter: Antonio Jose Gonzalez Martin
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Full session recording
Presenter: Keith Kerr
Session: Janssen - Expanding horizons for the targeted management of EGFR-Positive NSCLC
Resources:
Webcast